The raised price target from $12.5 to $28 by a reputable analyst at Goldman Sachs is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price of GeneDx Holdings. However, the Neutral rating suggests that the analyst does not see significant upside potential beyond the new price target.